Patents by Inventor Pierre Coulie

Pierre Coulie has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Anti-GARP protein
    Patent number: 11230603
    Abstract: The present invention relates to a protein binding to GARP in the presence of TGF-? and uses thereof.
    Type: Grant
    Filed: February 14, 2020
    Date of Patent: January 25, 2022
    Assignees: LUDWIG INSTITUTE FOR CANCER RESEARCH LTD, UNIVERSITÉ CATHOLIQUE DE LOUVAIN, argenx BVBA
    Inventors: Sophie Lucas, Pierre Coulie, Julia Cuende Villasur, Laure Dumoutier, Jean-Christophe Renauld, Sebastian van der Woning, Michael Saunders, Hans De Haard, Gitte De Boeck
  • GARP-TGF-BETA ANTIBODIES
    Publication number: 20210324061
    Abstract: The present invention relates to antibodies and antigen binding fragments thereof, which bind to a complex of GARP and TGF-?1, particularly a complex of human GARP and human TGF-?1. These antibodies and antigen binding fragments exhibit a combination of advantageous properties including high affinity antigen binding and the ability to inhibit the release of active TGF-? from regulatory T cells. The antibodies and antigen binding fragments of the present invention are relatively resistant to deamidation, isomerization and oxidation, such that they display improved stability.
    Type: Application
    Filed: November 12, 2020
    Publication date: October 21, 2021
    Inventors: Sebastian van der Woning, Filip Borgions, Torsten Dreier, Lore Mariën, Gitte De Boeck, Stéphanie Liénart, Sophie Lucas, Pierre Coulie
  • Nucleic acids encoding GARP-TGF-beta 1 antibodies
    Patent number: 10875914
    Abstract: The present invention relates to antibodies and antigen binding fragments thereof, which bind to a complex of GARP and TGF-?1, particularly a complex of human GARP and human TGF-?1. These antibodies and antigen binding fragments exhibit a combination of advantageous properties including high affinity antigen binding and the ability to inhibit the release of active TGF-? from regulatory T cells. The antibodies and antigen binding fragments of the present invention are relatively resistant to deamidation, isomerization and oxidation, such that they display improved stability.
    Type: Grant
    Filed: May 10, 2019
    Date of Patent: December 29, 2020
    Assignees: argenx BVBA, Université Catholique de Louvain
    Inventors: Sebastian van der Woning, Filip Borgions, Torsten Dreier, Lore Mariën, Gitte De Boeck, Stëphanie Liénart, Sophie Lucas, Pierre Coulie
  • Method of screening for anti-GARP antibodies
    Patent number: 10822424
    Abstract: The present invention relates to a protein binding to GARP in the presence of TGF-? and uses thereof.
    Type: Grant
    Filed: March 29, 2019
    Date of Patent: November 3, 2020
    Assignee: Université catholique de Louvain
    Inventors: Sophie Lucas, Stéphanie Lienart, Pierre Coulie
  • GARP-TGF-? 1 IGG antibodies
    Patent number: 10793627
    Abstract: The present invention relates to antibodies and antigen binding fragments thereof, which bind to a complex of GARP and TGF-?1, particularly a complex of human GARP and human TGF-?1. These antibodies and antigen binding fragments exhibit a combination of advantageous properties including high affinity antigen binding and the ability to inhibit the release of active TGF-? from regulatory T cells. The antibodies and antigen binding fragments of the present invention are relatively resistant to deamidation, isomerization and oxidation, such that they display improved stability.
    Type: Grant
    Filed: November 27, 2019
    Date of Patent: October 6, 2020
    Assignees: argenx BVBA, Université Catholique de Louvain
    Inventors: Sebastian van der Woning, Filip Borgions, Torsten Dreier, Lore Mariën, Gitte De Boeck, Stéphanie Liénart, Sophie Lucas, Pierre Coulie
  • ANTI-GARP PROTEIN AND USES THEREOF
    Publication number: 20200181276
    Abstract: The present invention relates to a protein binding to GARP in the presence of TGF-? and uses thereof.
    Type: Application
    Filed: February 14, 2020
    Publication date: June 11, 2020
    Inventors: Sophie Lucas, Pierre Coulie, Julia Cuende Villasur, Laure Dumoutier, Jean-Christophe Renauld, Sebastian van der Woning, Michael Saunders, Hans De Haard, Gitte De Boeck
  • Antibody against a complex between human GARP and latent TGF-?
    Patent number: 10604579
    Abstract: The present invention relates to a protein binding to GARP in the presence of TGF-? and uses thereof.
    Type: Grant
    Filed: May 9, 2018
    Date of Patent: March 31, 2020
    Assignees: LUDWIG INSTITUTE FOR CANCER RESEARCH LTD, UNIVERSITÉ CATHOLIQUE DE LOUVAIN, argenx BVBA
    Inventors: Sophie Lucas, Pierre Coulie, Julia Cuende Villasur, Laure Dumoutier, Jean-Christophe Renauld, Sebastian Van Der Woning, Michael Saunders, Hans De Haard, Gitte De Boeck
  • GARP-TGF-BETA 1 ANTIBODIES
    Publication number: 20200095311
    Abstract: The present invention relates to antibodies and antigen binding fragments thereof, which bind to a complex of GARP and TGF-?1, particularly a complex of human GARP and human TGF-?1. These antibodies and antigen binding fragments exhibit a combination of advantageous properties including high affinity antigen binding and the ability to inhibit the release of active TGF-? from regulatory T cells. The antibodies and antigen binding fragments of the present invention are relatively resistant to deamidation, isomerization and oxidation, such that they display improved stability.
    Type: Application
    Filed: November 27, 2019
    Publication date: March 26, 2020
    Inventors: Sebastian van der Woning, Filip Borgions, Torsten Dreier, Lore Mariën, Gitte De Boeck, Stéphanie Liénart, Sophie Lucas, Pierre Coulie
  • GARP-TGF-BETA 1 ANTIBODIES
    Publication number: 20190375832
    Abstract: The present invention relates to antibodies and antigen binding fragments thereof, which bind to a complex of GARP and TGF-?1, particularly a complex of human GARP and human TGF-?1. These antibodies and antigen binding fragments exhibit a combination of advantageous properties including high affinity antigen binding and the ability to inhibit the release of active TGF-? from regulatory T cells. The antibodies and antigen binding fragments of the present invention are relatively resistant to deamidation, isomerization and oxidation, such that they display improved stability.
    Type: Application
    Filed: May 10, 2019
    Publication date: December 12, 2019
    Inventors: Sebastian van der Woning, Filip Borgions, Torsten Dreier, Lore Mariën, Gitte De Boeck, Stéphanie Liénart, Sophie Lucas, Pierre Coulie
  • GARP-TGF-beta 1 antibodies
    Patent number: 10479829
    Abstract: The present invention relates to antibodies and antigen binding fragments thereof, which bind to a complex of GARP and TGF-?1, particularly a complex of human GARP and human TGF-?1. These antibodies and antigen binding fragments exhibit a combination of advantageous properties including high affinity antigen binding and the ability to inhibit the release of active TGF-? from regulatory T cells. The antibodies and antigen binding fragments of the present invention are relatively resistant to deamidation, isomerization and oxidation, such that they display improved stability.
    Type: Grant
    Filed: May 11, 2018
    Date of Patent: November 19, 2019
    Assignees: argenx BVBA, Université Catholique de Louvian
    Inventors: Sebastian Van der Woning, Filip Borgions, Torsten Dreier, Lore Mariën, Gitte De Boeck, Stéphanie Liénart, Sophie Lucas, Pierre Coulie
  • ANTI-GARP PROTEIN AND USES THEREOF
    Publication number: 20190016811
    Abstract: The present invention relates to a protein binding to GARP in the presence of TGF-ß and uses thereof.
    Type: Application
    Filed: May 9, 2018
    Publication date: January 17, 2019
    Inventors: Sophie Lucas, Pierre Coulie, Julia Cuende Villasur, Laure Dumoutier, Jean-Christophe Renauld, Sebastian Van Der Woning, Michael Saunders, Hans De Haard, Gitte De Boeck
  • GARP-TGF-BETA ANTIBODIES
    Publication number: 20180327487
    Abstract: The present invention relates to antibodies and antigen binding fragments thereof, which bind to a complex of GARP and TGF-?1, particularly a complex of human GARP and human TGF-?1. These antibodies and antigen binding fragments exhibit a combination of advantageous properties including high affinity antigen binding and the ability to inhibit the release of active TGF-? from regulatory T cells. The antibodies and antigen binding fragments of the present invention are relatively resistant to deamidation, isomerization and oxidation, such that they display improved stability.
    Type: Application
    Filed: May 11, 2018
    Publication date: November 15, 2018
    Inventors: Sebastian Van der Woning, Filip Borgions, Torsten Dreier, Lore Mariën, Federica Linty, Gitte De Boeck, Hans De Haard, Stéphanie Liénart, Sophie Lucas, Pierre Coulie, Michael Saunders
  • Method for inhibiting the immune suppressive function of human T regulatory cells by administering an anti-GARP monoclonal antibody
    Patent number: 10000572
    Abstract: The present invention relates to an antibody binding to the transmembrane protein ‘glycoprotein A repetitions predominant’ (GARP) in the presence of TGF-? and uses thereof.
    Type: Grant
    Filed: August 1, 2014
    Date of Patent: June 19, 2018
    Assignees: UNIVERSITÉ CATHOLIQUE DE LOUVAIN, LUDWIG INSTITUTE FOR CANCER RESEARCH LTD
    Inventors: Sophie Lucas, Pierre Coulie, Julia Cuende Villasur, Laure Dumoutier, Jean-Christophe Renauld
  • ANTI-GARP PROTEIN AND USES THEREOF
    Publication number: 20160272717
    Abstract: The present invention relates to an antibody binding to the transmembrane protein ‘glycoprotein A repetitions predominant’ (GARP) in the presence of TGF-? and uses thereof.
    Type: Application
    Filed: August 1, 2014
    Publication date: September 22, 2016
    Inventors: Sophie Lucas, Pierre Coulie, Julia Cuende Villasur, Laure Dumoutier, Jean-Christophe Renauld, Sebastian Van De Woning, Michael Saunders, Hans De Haard, Gitte De Boeck
  • ANTI-GARP PROTEIN AND USES THEREOF
    Publication number: 20160251438
    Abstract: The present invention relates to a protein binding to GARP in the presence of TGF-? and uses thereof.
    Type: Application
    Filed: February 2, 2016
    Publication date: September 1, 2016
    Inventors: Sophie Lucas, Sebastian Van De Woning, Michael Saunders, Hans De Haard, Gitte De Boeck, Pierre Coulie
  • MAGE-C2 antigenic peptides and uses thereof
    Patent number: 8143011
    Abstract: This invention relates to isolated peptides derived from MAGE-C2, nucleic acid molecules that encode MAGE-C2 and the isolated peptides derived from MAGE-C2, expression vectors comprising the nucleic acid molecules, host cells transformed or transfected with the nucleic acid molecules or the expression vectors, and to tetramers comprising the peptides, HLA molecules, ?2 microglobulin and a first and second binding partner. This invention also relates to methods for using the peptides, nucleic acid molecules, expression vectors, tetramers and complexes of this invention as well as to cytolytic T cells which recognize the peptides in complex with an HLA molecule.
    Type: Grant
    Filed: July 13, 2011
    Date of Patent: March 27, 2012
    Assignee: Ludwig Institute for Cancer Research
    Inventors: Wenbin Ma, Benoit Van Den Eynde, Thierry Boon-Falleur, Catherine Germeau, Pierre Coulie, Nathalie Vigneron
  • MAGE-C2 ANTIGENIC PEPTIDES AND USES THEREOF
    Publication number: 20110305722
    Abstract: This invention relates to isolated peptides derived from MAGE-C2, nucleic acid molecules that encode MAGE-C2 and the isolated peptides derived from MAGE-C2, expression vectors comprising the nucleic acid molecules, host cells transformed or transfected with the nucleic acid molecules or the expression vectors, and to tetramers comprising the peptides, HLA molecules, ?2 microglobulin and a first and second binding partner. This invention also relates to methods for using the peptides, nucleic acid molecules, expression vectors, tetramers and complexes of this invention as well as to cytolytic T cells which recognize the peptides in complex with an HLA molecule.
    Type: Application
    Filed: July 13, 2011
    Publication date: December 15, 2011
    Inventors: Wenbin MA, Benoit Van Den Eynde, Thierry Boon-Falleur, Catherine Germeau, Pierre Coulie
  • MAGE-C2 antigenic peptides and uses therefor
    Publication number: 20090233315
    Abstract: This invention relates to isolated peptides derived from MAGE-C2, nucleic acid molecules that encode MAGE-C2 and the isolated peptides derived from MAGE-C2, expression vectors comprising the nucleic acid molecules, host cells transformed or transfected with the nucleic acid molecules or the expression vectors, and to tetramers comprising the peptides, HLA molecules, ?2 microglobulin and a first and second binding partner. This invention also relates to methods for using the peptides, nucleic acid molecules, expression vectors, tetramers and complexes of this invention as well as to cytolytic T cells which recognize the peptides in complex with an HLA molecule.
    Type: Application
    Filed: May 8, 2009
    Publication date: September 17, 2009
    Inventors: Wenbin Ma, Benoit Van Den Eynde, Thierry Boon-Falleur, Catherine Germeau, Pierre Coulie
  • MAGE-C2 antigenic peptides and uses thereof
    Patent number: 7547517
    Abstract: This invention relates to isolated peptides derived from MAGE-C2, nucleic acid molecules that encode MAGE-C2 and the isolated peptides derived from MAGE-C2, expression vectors comprising the nucleic acid molecules, host cells transformed or transfected with the nucleic acid molecules or the expression vectors, and to tetramers comprising the peptides, HLA molecules, ?2 microglobulin and a first and second binding partner. This invention also relates to methods for using the peptides, nucleic acid molecules, expression vectors, tetramers and complexes of this invention as well as to cytolytic T cells which recognize the peptides in complex with an HLA molecule.
    Type: Grant
    Filed: September 26, 2003
    Date of Patent: June 16, 2009
    Assignee: Ludwig Institute for Cancer Research
    Inventors: Wenbin Ma, Benoit Van Den Eynde, Thierry Boon-Falleur, Catherine Germeau, Pierre Coulie
  • MAGE-C2 antigenic peptides and uses thereof
    Publication number: 20040214779
    Abstract: This invention relates to isolated peptides derived from MAGE-C2, nucleic acid molecules that encode MAGE-C2 and the isolated peptides derived from MAGE-C2, expression vectors comprising the nucleic acid molecules, host cells transformed or transfected with the nucleic acid molecules or the expression vectors, and to tetramers comprising the peptides, HLA molecules, &bgr;2 microglobulin and a first and second binding partner. This invention also relates to methods for using the peptides, nucleic acid molecules, expression vectors, tetramers and complexes of this invention as well as to cytolytic T cells which recognize the peptides in complex with an HLA molecule.
    Type: Application
    Filed: September 26, 2003
    Publication date: October 28, 2004
    Applicant: LUDWIG INSTITUTE FOR CANCER RESEARCH
    Inventors: Wenbin Ma, Benoit Van Den Eynde, Thierry Boon-Falleur, Catherine Germeau, Pierre Coulie